Allogene Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Filed June 15, 2023, regarding the company’s June 13, 2023 Annual Meeting of Stockholders. The filing reports voting results and does not provide quarterly or annual financial statements.
The filing states that 145,781,920 common shares were outstanding and entitled to vote as of April 17, 2022, identified as the record date for the meeting. This date appears unusual relative to the 2023 meeting and should be verified against the company’s proxy materials.
Voting Results and Corporate Actions
| Proposal | Result |
|---|---|
| Election of four Class II directors | Deborah Messemer, Vicki Sato, Ph.D., Todd Sisitsky, and Owen Witte, M.D. were elected to serve until the 2026 Annual Meeting and until their successors are elected and qualified. |
| Advisory approval of named executive officer compensation | Approved. |
| Ratification of Ernst & Young LLP | Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. |
Detailed Vote Counts
| Director | For | Withheld | Broker non-votes |
|---|---|---|---|
| Deborah Messemer | 90,975,252 | 15,799,554 | 13,946,626 |
| Vicki Sato, Ph.D. | 105,736,345 | 1,038,461 | 13,946,626 |
| Todd Sisitsky | 86,678,264 | 20,096,542 | 13,946,626 |
| Owen Witte, M.D. | 88,677,813 | 18,096,993 | 13,946,626 |
| Proposal | For | Against | Abstentions | Broker non-votes |
|---|---|---|---|---|
| Executive compensation | 73,082,912 | 31,751,974 | 1,939,920 | 13,946,626 |
| Auditor ratification | 120,675,447 | 36,870 | 9,115 | 0 |
Financial Metrics, Guidance, and Risks
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, financial guidance, operating outlook, or other financial metrics. It also does not disclose new material risks, contingencies, or unusual financial items.
Most Important Facts to Verify
- Confirm the stated April 17, 2022 record date, which appears inconsistent with the 2023 Annual Meeting.
- Review the proxy statement for the basis of the executive compensation advisory vote and director elections.
- Confirm the elected directors’ terms through the 2026 Annual Meeting.
- Verify Ernst & Young LLP’s appointment for the fiscal year ending December 31, 2023.